26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin d3 profile

26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: long lasting analog of calcitriol; RN given refers to (1alpha,3beta,5Z,7E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5282190
CHEMBL ID	2106158
SCHEMBL ID	3754
SCHEMBL ID	15263837
MeSH ID	M0120543

Synonym
26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxyvitamin d3 / 26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxycholecalciferol
(5z,7e)-(1s,3r)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
LMST03020089
9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, 26,26,26,27,27,27-hexafluoro-, (1-alpha,3-beta,5z,7e)-
calcitriol hexafluoride
ro 23-4194
hornel, fulstan
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin d3
st 630
falecalcitriol [inn]
(+)-(5z,7e)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
HY-32342
f6-1alpha,25(oh)2d3
gtpl2781
hexafluorocalcitriol
fulstan
horner
ro-23-4194
falecalcitriol
dsc-103
st-630
flocalcitriol
falecalcitriol (jan/inn)
83805-11-2
hornel (tn)
D01662
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
unii-g70a8514t8
g70a8514t8 ,
falecalcitoriol
hornel
CHEMBL2106158
CS-0801
falecalcitriol [mart.]
falecalcitoriol [jan]
falecalcitriol [jan]
falecalcitriol [who-dd]
(+)-(5z,7e)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1.alpha.,3.beta.,25-triol
SCHEMBL3754
SCHEMBL15263837
(1r,3s,z)-5-(2-((1r,3as,7ar,e)-7a-methyl-1-((r)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl)octahydro-4h-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
AKOS025312291
f6vd3
Q5431843
falecalcitol
(1s,3r,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
F84840
MS-29711
DTXSID601027560

Excerpt	Relevance	Reference
"3 mM NaB, the dosage of F6-1,25-(OH)2D3 required to inhibit cell growth and colony formation and to induce cell differentiation was significantly reduced."	( Effect of hexafluoro-1,25-dihydroxyvitamin D3 and sodium butyrate combination on differentiation and proliferation of HL-60 leukemia cells. Eguchi, T; Ikekawa, N; Saijo, N; Tanaka, Y; Yoshida, M, )	0.13
" The dosage of both drugs was adjusted to maintain the initial serum calcium levels, and the relative change (%change) of serum biochemical parameters were compared."	( Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Akiba, T; Ando, R; Chida, Y; Inoue, A; Ishida, Y; Kurihara, S; Marumo, F; Ohashi, Y; Owada, A; Shinoda, T, 1998)	0.3
"6 times higher at 6, 24, and 48 h postdosing than after dosing with [1beta-3H] 1alpha,25(OH)2 vitamin D3."	( Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds. Kanamaru, H; Komuro, S; Sato, M, 2003)	0.32

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (11.90)	18.7374
1990's	19 (45.24)	18.2507
2000's	15 (35.71)	29.6817
2010's	3 (7.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (11.11%)	5.53%
Reviews	5 (11.11%)	6.00%
Case Studies	2 (4.44%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (73.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	3.27	1	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
thymidine [no description available]	2	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.4	2	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	1.98	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
hexafluoroacetone hexafluoroacetone: structure; RN given refers to parent cpd. hexafluoroacetone : A ketone that is acetone in which all the methyl hydrogens are replaced by fluoro groups.	3.27	1	0	ketone; perfluorinated compound	NMR chemical shift reference compound
hexafluoroisopropanol 1,1,1,3,3,3-hexafluoropropan-2-ol : An organofluorine compound formed by substitution of all the methyl protons in propan-2-ol by fluorine. It is a metabolite of inhalation anesthetic sevoflurane.	3.27	1	0	organofluorine compound; secondary alcohol	drug metabolite
raloxifene hydrochloride Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.	2	1	0	hydrochloride	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	1.98	1	0	carbamate ester; oxazolidinone	metabolite
cinacalcet cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.	2.13	1	0	(trifluoromethyl)benzenes; naphthalenes; secondary amino compound	calcimimetic; P450 inhibitor
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	10.23	42	5	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	4.04	2	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	4.01	4	0	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
paricalcitol [no description available]	4.04	2	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	4.06	3	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
maxacalcitol maxacalcitol: structure given in first source	3.56	2	0	organic molecular entity
24,24-difluoro-1,25-dihydroxyvitamin d3 24,24-difluoro-1,25-dihydroxyvitamin D3: RN given refers to (1alpha,3beta,5Z,7E)-isomer	2.38	2	0
st 232 26,26,26,27,27,27-hexafluoro-1,23,25-trihydroxyvitamin D3: RN given refers to (1alpha,3beta,5Z,7E,23S)-isomer; RN for cpd without isomeric designation not avail 12/92	4.01	4	0
1,25-dihydroxy-24-oxo-16-ene-vitamin d3 [no description available]	2	1	0	vitamin D
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	1.98	1	0
1 alpha,24-dihydroxyvitamin d3 1 alpha,24-dihydroxyvitamin D3: RN refers to (1alpha,3beta,5Z,7E)-isomer; formulated in ointment at a concentration of 4 microg/g, for treatment of mild psoriasis	1.98	1	0

Condition	Relationship Strength	Studies	Trials
Complications of Diabetes Mellitus [description not available]	2.13	1	0
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.13	1	0
Secondary Hyperparathyroidism [description not available]	7.89	9	3
Chronic Kidney Failure [description not available]	7.07	7	2
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	2.13	1	0
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.13	1	0
Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.	7.89	9	3
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	7.07	7	2
Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.	4.71	2	1
Idiopathic Hypoparathyroidism A condition of low or absent PTH level and HYPOCALCEMIA. It usually occurs as part of an autoimmune syndrome.	2.92	1	0
Adult Rickets [description not available]	2.92	1	0
Rachitis [description not available]	3.3	2	0
Hypoparathyroidism A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.	2.92	1	0
Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.	2.92	1	0
Leucocythaemia [description not available]	1.96	1	0
Granulocytic Leukemia [description not available]	1.96	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1.96	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	1.96	1	0
Acute Promyelocytic Leukemia [description not available]	2.39	2	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2.39	2	0
Bone Loss, Osteoclastic [description not available]	2.9	4	0
Deficiency, Vitamin D [description not available]	2.67	3	0
Vitamin D Deficiency A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)	2.67	3	0
Palmoplantaris Pustulosis [description not available]	3.79	2	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	3.79	2	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	2.01	1	0
Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.	1.98	1	0
Hypocalcemia Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)	1.98	1	0
Age-Related Osteoporosis [description not available]	1.97	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	1.97	1	0
Acute Myelogenous Leukemia [description not available]	1.96	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1.96	1	0

26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin d3

Description

Cross-References

Synonyms (49)

Research Excerpts

Dosage Studied

Research

Studies (42)

Market Indicators

Research Demand Index: 10.89

Study Types